nChroma Bio is a pioneering biotechnology company redefining the future of in vivo targeted genetic medicine to treat a wide array of diseases and bring cures to patients. The company’s integrated product engine tackles significant limitations of existing genetic medicine approaches by enabling safe, precise and specific in vivo delivery. nChroma’s near clinical-stage development candidate, CRMA-1001, is a liver-targeted therapy in development as a potential functional cure for chronic hepatitis B and hepatitis D that leverages the power of epigenetics, nature's innate mechanism for gene regulation. Guided by a world-class team at the forefront of genetic medicine, founded by renowned pioneers in the field, and supported by top-tier investors, the company is uniquely positioned to deliver groundbreaking therapies with programmable tissue specificity, unlocking highly potent, durable and targeted gene regulation for the liver and beyond.
Company Details
- Employees
- 91
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.nchromabio.com/
Nchroma Bio Questions
Nchroma Bio's website is https://www.nchromabio.com/
Nchroma Bio's LinkedIn profile is https://www.linkedin.com/company/nchroma-bio
Nchroma Bio has
91 employees.
View email and phone details for 91
employees at Nchroma Bio.
Nchroma Bio's industry is
Biotechnology Research
Nchroma Bio's top competitors are
Airna,
Beam Therapeutics,
Chroma Medicine,
Orna Therapeutics,
Prime Medicine, Inc.,
Angitia Biopharmaceuticals,
Nvelop Therapeutics,
Verve Therapeutics,
Tessera Therapeutics,
Vertex Pharmaceuticals.
Nchroma Bio's categories are Biotechnology Research
Nchroma Bio's founding year is 2024
